Oric PharmaceuticalsORIC
ORIC
About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Employees: 112
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,838% more call options, than puts
Call options by funds: $155K | Put options by funds: $8K
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
49% more capital invested
Capital invested by funds: $481M [Q2] → $715M (+$234M) [Q3]
9% more funds holding
Funds holding: 112 [Q2] → 122 (+10) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 38
1.88% less ownership
Funds ownership: 100.87% [Q2] → 98.99% (-1.88%) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
78%
upside
Avg. target
$19.83
107%
upside
High target
$21
120%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 43% 1-year accuracy 60 / 139 met price target | 120%upside $21 | Buy Reiterated | 4 Nov 2024 |
Wells Fargo | 109%upside $20 | Overweight Initiated | 31 Oct 2024 |
Jones Trading Soumit Roy 20% 1-year accuracy 2 / 10 met price target | 78%upside $17 | Buy Initiated | 31 Oct 2024 |
HC Wainwright & Co. Robert Burns 43% 1-year accuracy 60 / 139 met price target | 120%upside $21 | Buy Reiterated | 18 Sept 2024 |
Wedbush David Nierengarten 43% 1-year accuracy 23 / 53 met price target | 109%upside $20 | Outperform Reiterated | 10 Sept 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in December:
Positive
MarketBeat
2 weeks ago
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals NASDAQ: ORIC is a small-cap pharma stock. It aims to make a difference with its potentially "best-in-class" treatments.
Neutral
GlobeNewsWire
1 month ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November:
Neutral
GlobeNewsWire
1 month ago
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2024 (the “Grant Date”), ORIC granted a total of 61,800 non-qualified stock options and 10,400 restricted stock units to two new non-executive employees who began their employment with ORIC in October 2024.
Neutral
GlobeNewsWire
1 month ago
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 23-25, 2024, in Barcelona, Spain.
Neutral
GlobeNewsWire
2 months ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2024 (the “Grant Date”), ORIC granted a total of 92,400 non-qualified stock options and 16,300 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2024.
Neutral
GlobeNewsWire
2 months ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024.
Neutral
GlobeNewsWire
3 months ago
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:
Neutral
GlobeNewsWire
3 months ago
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
Initiated dosing of ORIC-944 in combinations with NUBEQA ® (darolutamide) and ERLEADA ® (apalutamide) in the ongoing Phase 1b trial for prostate cancer
Neutral
GlobeNewsWire
4 months ago
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs.
Charts implemented using Lightweight Charts™